300267.SZ
300267.SZ
CNE100001781
ER-KANG
Loading chart...

Company Profile

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients, such as pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprising of hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.

Related stocks

600557.SS
600557.SS • China
JIANGSU KANION PHARMACEUTICAL C
12.4 CNY
1.05B USD 1Y -18.4%
300401.SZ
300401.SZ • China
GARDEN BIO-CHEM
14.65 CNY
1.19B USD 1Y +2.5%
000650.SZ
000650.SZ • China
RENHE PHARMACY CO LTD
5.29 CNY
1.11B USD 1Y -12.9%
600195.SS
600195.SS • China
CHINA ANIMAL HUSBANDRY INDUSTRY
6.73 CNY
1.03B USD 1Y -6%
300702.SZ
300702.SZ • China
TIANYU PHARMA
22.18 CNY
1.15B USD 1Y -13.6%
002737.SZ
002737.SZ • China
SFPM
11.53 CNY
1.01B USD 1Y -24.8%
301263.SZ
301263.SZ • China
TEK
19.14 CNY
1.22B USD 1Y -31.8%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
47.7% p.a.
Max Drawdown (5Y)
-60.1%
Sharpe Ratio (5Y)
-0.15
Beta Factor
0.49
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (52.0%) is noticeably higher than the 5Y average (47.7%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (47.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.1% in the extended horizon.
ende